ProKidney Corp. director Brian JG Pereira sold his entire holding of 757,164 Class A Common Stock shares.
The transactions occurred between August 18 and August 20, 2026. Total proceeds from the divestment reached approximately $1.07 million. Weighted average prices for the shares ranged from $1.3712 to $1.4407.
Pereira’s direct and indirect beneficial ownership in the company is now zero. ProKidney is currently focused on rilparencel, its lead cell therapy program for chronic kidney disease.